Clinical efficacy of entecavir in treatment of chronic hepatitis B
DOI:
Author:
Affiliation:

Clc Number:

R512.6+2

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Comments
    Abstract:

    ObjectiveTo investigate clinical efficacy and safety of entecavir for chronic hepatitis B (CHB) patients. MethodsSixtytwo CHB patients were randomly divided into treatment group and control group, treatment group (30 cases) were given entecavir 0.5mg/d, control group (32 cases) were given lamivudine 100mg / d, serum alanine transaminase (ALT) normalization rate, rates of HBV DNA value below the detection limit ,HBeAg seroconversion rate, and adverse effect rate were observed at week 4,12,24 and 48 of treatment.ResultsAt week 4,12,24 and 48 of treatment, rate of serum HBV DNA value below the detection limit was 63.33%, 76.67%, 86.67%, and 93.33% in treatment group and 37.50%, 50.00%, 56.25% , and 65.63% in control group, respectively, the difference was statistically significant (P<0.05 or P<0.01); there was no statistical difference in ALT normalization rate, HBeAg negative seroconversion rate, and the adverse effect rate between two groups (both P>0.05).ConclusionEntecavir can rapidly reduce the serum HBV DNA value of patients with CHB, effectively inhibit hepatitis B virus replication, and with good safety.

    Reference
    Related
Get Citation

李丹,龙云铸,赵斌,等.恩替卡韦治疗慢性乙型肝炎临床疗效[J].中国感染控制杂志英文版,2011,10(4):263-265.
LI Dan, LONG Yunzhu, ZHAO Bin, et al. Clinical efficacy of entecavir in treatment of chronic hepatitis B[J]. Chin J Infect Control, 2011,10(4):263-265.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:February 25,2011
  • Revised:April 12,2011
  • Adopted:
  • Online: July 30,2011
  • Published: